We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical is prioritizing R&D over near-term leverage to support long-term growth.
AI/ML, robotics, imaging and software are key areas of its R&D investment strategy.
ISRG is expanding into GI, cardiac and lung procedures to broaden its clinical reach.
Intuitive Surgical (ISRG - Free Report) is deliberately prioritizing research and development to fuel long-term growth, offsetting near-term challenges from macroeconomic uncertainty, healthcare policy changes and international competitive pressures.
In the second quarter, management said R&D expenses are growing faster than SG&A, a trend expected to continue through the remainder of 2026. The strategy reflects a long-term objective — using innovation to reach more patients, expand into new disease areas and strengthen the company's competitive differentiation rather than focusing on near-term operating leverage.
Artificial intelligence and machine learning are central to this investment strategy. Intuitive Surgical is directing R&D resources across AI/ML, robotics, instrumentation, imaging and advanced materials, while continuing to develop software capabilities around its robotic platforms. Management views these investments as tools to improve reliability, usability, efficiency and throughput, ultimately creating differentiated solutions and reducing the total cost of care.
The company is simultaneously expanding beyond its established procedures. Its next-generation flexible robotic endoscope is being developed for gastrointestinal applications, with a foundational noncommercial system recently submitted for FDA 510(k) clearance. This could provide Intuitive Surgical with a pathway into GI robotics and additional high-volume procedures over time.
Cardiac and lung interventions represent other important areas of R&D optionality. Cardiac procedures accelerated 39% in the second quarter, as Intuitive Surgical continues developing cardiac-specific instruments to support broader adoption. On the lung side, Ion procedures increased 36% to 48,000, with cumulative procedures exceeding 400,000. Development of the ROSE and EBUS programs, alongside expansion into 12 countries outside the United States, could broaden Ion's clinical utility and international opportunity.
The financial rationale is therefore centered on long-term benefits. Intuitive Surgical is effectively sacrificing some near-term expense leverage to build a broader technology and clinical moat. With more procedures, new indications and differentiated capabilities, the company can expand its addressable market while strengthening its ecosystem. Management's willingness to increase R&D spending despite macroeconomic headwinds signals that it views innovation, rather than cost cutting, as the more important driver of durable growth.
Peer Updates
Edwards Lifesciences (EW - Free Report) is maintaining substantial R&D investment to extend its structural-heart leadership and create multiple future growth platforms. In the second quarter, R&D expense was $279 million, or 16% of sales, up from $276 million a year earlier, with management expecting R&D to account for 17% of 2026 sales.
The spending is focused on expanding the structural-heart portfolio, including next-generation SAPIEN X4S, PASCAL with Capture Clarity, EVOQUE and SAPIEN M3. Edwards is also generating clinical evidence to support new indications, including moderate and asymptomatic aortic stenosis. Management views these investments as multiyear opportunities capable of supporting roughly 10% long-term annual sales growth and strengthening its competitive moat through differentiated technology, evidence and indication expansion.
Glaukos (GKOS - Free Report) is channeling its strong revenue growth into R&D and clinical development to expand its ophthalmology pipeline and reinforce its competitive advantage. CFO Alex Thurman noted that R&D increased $8 million sequentially in the second quarter, with management continuing to prioritize investment in clinical programs even as operating leverage improves.
The pipeline spans five novel therapeutic platforms, 13 publicly disclosed programs and additional undisclosed assets, including Phase IIb/III development of next-generation iDose TREX, Phase IIIb work on iDose TRIO, a corneal-health screening device, customized third-generation iLink therapy and other programs. Management said the objective is to maximize both near- and long-term top-line growth while supporting two transformational commercial drivers, iDose TR and Epioxa. This sustained clinical investment could create successive product cycles, expand treatment categories and reinforce Glaukos' differentiated technology moat.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 34.2% so far this year compared with a 7.3% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 32.64X, above the industry average. However, it is significantly lower than its five-year median of 68.4X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Key Takeaways
Intuitive Surgical (ISRG - Free Report) is deliberately prioritizing research and development to fuel long-term growth, offsetting near-term challenges from macroeconomic uncertainty, healthcare policy changes and international competitive pressures.
In the second quarter, management said R&D expenses are growing faster than SG&A, a trend expected to continue through the remainder of 2026. The strategy reflects a long-term objective — using innovation to reach more patients, expand into new disease areas and strengthen the company's competitive differentiation rather than focusing on near-term operating leverage.
Artificial intelligence and machine learning are central to this investment strategy. Intuitive Surgical is directing R&D resources across AI/ML, robotics, instrumentation, imaging and advanced materials, while continuing to develop software capabilities around its robotic platforms. Management views these investments as tools to improve reliability, usability, efficiency and throughput, ultimately creating differentiated solutions and reducing the total cost of care.
The company is simultaneously expanding beyond its established procedures. Its next-generation flexible robotic endoscope is being developed for gastrointestinal applications, with a foundational noncommercial system recently submitted for FDA 510(k) clearance. This could provide Intuitive Surgical with a pathway into GI robotics and additional high-volume procedures over time.
Cardiac and lung interventions represent other important areas of R&D optionality. Cardiac procedures accelerated 39% in the second quarter, as Intuitive Surgical continues developing cardiac-specific instruments to support broader adoption. On the lung side, Ion procedures increased 36% to 48,000, with cumulative procedures exceeding 400,000. Development of the ROSE and EBUS programs, alongside expansion into 12 countries outside the United States, could broaden Ion's clinical utility and international opportunity.
The financial rationale is therefore centered on long-term benefits. Intuitive Surgical is effectively sacrificing some near-term expense leverage to build a broader technology and clinical moat. With more procedures, new indications and differentiated capabilities, the company can expand its addressable market while strengthening its ecosystem. Management's willingness to increase R&D spending despite macroeconomic headwinds signals that it views innovation, rather than cost cutting, as the more important driver of durable growth.
Peer Updates
Edwards Lifesciences (EW - Free Report) is maintaining substantial R&D investment to extend its structural-heart leadership and create multiple future growth platforms. In the second quarter, R&D expense was $279 million, or 16% of sales, up from $276 million a year earlier, with management expecting R&D to account for 17% of 2026 sales.
The spending is focused on expanding the structural-heart portfolio, including next-generation SAPIEN X4S, PASCAL with Capture Clarity, EVOQUE and SAPIEN M3. Edwards is also generating clinical evidence to support new indications, including moderate and asymptomatic aortic stenosis. Management views these investments as multiyear opportunities capable of supporting roughly 10% long-term annual sales growth and strengthening its competitive moat through differentiated technology, evidence and indication expansion.
Glaukos (GKOS - Free Report) is channeling its strong revenue growth into R&D and clinical development to expand its ophthalmology pipeline and reinforce its competitive advantage. CFO Alex Thurman noted that R&D increased $8 million sequentially in the second quarter, with management continuing to prioritize investment in clinical programs even as operating leverage improves.
The pipeline spans five novel therapeutic platforms, 13 publicly disclosed programs and additional undisclosed assets, including Phase IIb/III development of next-generation iDose TREX, Phase IIIb work on iDose TRIO, a corneal-health screening device, customized third-generation iLink therapy and other programs. Management said the objective is to maximize both near- and long-term top-line growth while supporting two transformational commercial drivers, iDose TR and Epioxa. This sustained clinical investment could create successive product cycles, expand treatment categories and reinforce Glaukos' differentiated technology moat.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 34.2% so far this year compared with a 7.3% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 32.64X, above the industry average. However, it is significantly lower than its five-year median of 68.4X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.